{"id":"insuline-glulisine","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Insulin glulisine is a recombinant human insulin analog engineered with amino acid substitutions (lysine at position B3 and glutamic acid at position B29) to accelerate absorption and onset of action compared to regular human insulin. It mimics the body's natural rapid insulin secretion in response to meals, binding to insulin receptors and facilitating cellular glucose uptake while suppressing hepatic glucose production and lipolysis.","oneSentence":"Insulin glulisine is a rapid-acting insulin analog that binds to insulin receptors on muscle and fat cells to promote glucose uptake and lower blood glucose levels.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:26.182Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT02509429","phase":"PHASE2","title":"Comparison of an Artificial Pancreas Versus Threshold Low Glucose Suspend in Type 1 Diabetic Children","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-06-16","conditions":"Type 1 Diabetes","enrollment":24},{"nctId":"NCT00545337","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":60},{"nctId":"NCT00546702","phase":"PHASE3","title":"Glulisine + Lantus in Type I Patients","status":"COMPLETED","sponsor":"Sanofi","startDate":"2004-09","conditions":"Diabetes Mellitus, Type 1","enrollment":142}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Insuline Glulisine","genericName":"Insuline Glulisine","companyName":"Sanofi","companyId":"sanofi","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin Glulisine is a protein-based insulin receptor agonist used to treat Type 1 Diabetes Mellitus. It belongs to the drug class of agonists and works by activating the insulin receptor.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}